drugset / Trial / NCT01337596
A Study of LY2951742 in Healthy Volunteers
RandomizedParallel-groupDouble-blindOther
Summary
To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects
Timeline
- Start
- 2011-04
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galcanezumab | Monoclonal antibody | 1 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 5 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 25 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 600 mg | Subcutaneous |